JKJonathan Koea

Jonathan Koea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan Koea has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • John L. McCall

    New Zealand Liver Transplant Unit Auckland City Hospital Auckland New Zealand

    5 shared publications
  • Michael Rodgers

    Hepatobiliary and Upper Gastrointestinal Unit, Departments of *Surgery, †Oncology and ‡Radiology, Auckland Hospital, Private Bag, Auckland, New Zealand

    3 shared publications
  • Andrew Holden

    Hepatobiliary and Upper Gastrointestinal Unit, Departments of *Surgery, †Oncology and ‡Radiology, Auckland Hospital, Private Bag, Auckland, New Zealand

    2 shared publications
  • Anthony Phillips

    Hepatobiliary and Upper Gastrointestinal Unit, Department of Surgery, Auckland Hospital, and the

    1 shared publication
  • Carlene Lawes

    Clinical Trials Research Unit, The University of Auckland, Auckland, New Zealand

    1 shared publication
  • Graeme Taylor

    1 shared publication

Latest Publications

  • Indigenous child health in New Zealand: Some surgical issues

    by Jonathan B Koea, Grant R Beban

    New Zealand Maori make up nearly 15% of the population of New Zealand, and their population has increased significantly in the last 20 years. Because of this, the average age of Maori is only 22.7 years with 35% of Maori aged 15 years or less. In spite of this youthful profile, the Maori population has high health needs with trauma, ear disease, respiratory disease and infectious diseases as significant causes of hospitalisation and death. The role of surgery in the management of three potentially preventable but significant health issues affecting Maori children – trauma, cutaneous sepsis (cellulitis and superficial abscess) and obesity – is reviewed.


  • Open Access

    Fast Track Liver Resection: The Effect of a Comprehensive Care Package and Analgesia with Single Dose Intrathecal Morphine with Gabapentin or Continuous Epidural Analgesia

    by Jonathan B. Koea, Yatin Young, Kerry Gunn

    Background. A comprehensive care package for patients undergoing hepatectomy was developed with the aim of minimal physiological disturbance in the peri-operative period. Peri-operative analgesia with few gastrointestinal effects and reduced requirement for intravenous (IV) fluid therapy was central to this plan. Methods. Data on 100 consecutive patients managed with continuous epidural infusion (n = 50; bupivicaine 0.125% and fentanyl 2𝜇g/mL at 0.1mL/kg/hr) or intrathecal morphine (n = 50; 300𝜇g in combination with oral gabapentin 1200mg preoperatively and 400mg bd postoperatively) was compared. Results. The epidural and intrathecal morphine groups were equivalent in terms of patient demographics, procedures and complications. Patients receiving intrathecal morphine received less intra-operative IV fluids (median 1500mL versus 2200mL, 𝑃=.06), less postoperative IV fluids (median 1200mL versus 4300mL, 𝑃=.03) than patients receiving epidural infusion. Patients managed with intrathecal morphine established a normal dietary intake sooner (16 hours versus 20 hours, 𝑃=.05) and had shorter hospital stays than those managed with epidural infusions (4.7 ± 0.9 days versus 6.8 ± 1.2 days, 𝑃=.02). Conclusions. Single dose intrathecal morphine is a safe and effective means of providing peri-operative analgesia. Patients managed with intrathecal morphine have reduced peri-operative physiological disturbance and return home within a few days of hepatic resection.


    • 4 July 2008
      • Vol. 121  (1277) , 61-9

    Cystic lesions of the liver: 6 years of surgical management in New Zealand.

    by Jonathan B Koea

    Cysts are a common radiological finding in the liver. Many affected patients do no require treatment. However a minority require further investigation and treatment for symptoms or risk of underlying malignancy. A computerised database of patients presenting to Auckland Hospital for the management of liver lesions was established in 2000. Details of demographics, presentation, investigations, management, and follow-up are entered prospectively. Forty-seven patients (36 female, median age 61, range 37-86 years) requiring surgical treatment of cystic liver lesions were identified from a total of over 800 patients enrolled in the database. Twenty-five patients presented with simple cysts, of whom 12 had radiological evidence of polycystic liver and kidney disease. All 25 patients were symptomatic and all were managed successfully with laparoscopic fenestration. Nine patients presented with complex cysts which were treated with liver resection. Of these patients, four had benign cysts, three had underlying biliary cystadenomas, and two had biliary cystadenocarcinomas. One patient with a biliary cystadenocarcinoma is dead of disease. The median follow-up for all 47 patients was 26 months. Cystic liver lesions can represent a spectrum of underlying conditions. All cysts require investigation and complex cysts or symptomatic simple cysts require further treatment.


  • GALL BLADDER POLYPS IN SCLEROSING CHOLANGITIS: DOES THE 1‐CM RULE APPLY?

    by Universe C Leung, Phillip Y Wong, Ross H Roberts, Jonathan B Koea

    Introduction:  Polyps of the gall bladder (PLG) are common findings in radiological investigations of the gall bladder and most are benign although carcinoma of the gall bladder can arise in PLG. In the general population PLG less than 1 cm in diameter are thought to have a low risk of malignancy and can be cautiously observed.Methods:  All patients undergoing surgical resection for gall bladder cancer were entered into a prospective database. Four patients with primary sclerosing cholangitis (PSC) presenting with gall bladder cancer in a PLG are studied.Results:  Four patients (two men; median age 46.5 years, range 37–71 years) presented with PLG and known histories of PSC. All patients were shown to have PLG of size between 7 mm × 8 mm and 25 mm × 14 mm on imaging with no radiological evidence of carcinoma. Tumour markers carcinoembryonic antigen and CA19‐9 were within the normal range in all patients. All patients were managed with cholecystectomy. Two patients with T1 tumours remain alive and well at 2 and 4 years post‐cholecystectomy. Of the remaining two patients with T2 tumours, one underwent re‐resection of the liver bed and portal lymph nodes and remains alive and well at 12 months. The remaining patient developed an abdominal wall recurrence 12 months after cholecystectomy. She has also undergone resection with postoperative radiation therapy and remains well after 12 months of clinical follow up.Conclusion:  Gall bladder polyps, which are common and are usually benign in the general population, are often malignant in PSC. Regardless of size, any PLG in a patient with PSC should be considered for cholecystectomy.


  • Focal nodular hyperplasia: what are the indications for resection?

    by Li Chun Hsee, John L. McCall, Jonathan B. Koea

    Focal nodular hyperplasia (FNH) lesions are benign liver lesions characterized by the presence of a vascular red‐brown or tan mass with nodules of benign hepatic parenchyma laced with fibrous septa that may extend out from a broad central stellate scar [ 1 x [1] Foster, J.H. and Berman, M.M. The benign lesions: adenoma and focal nodular hyperplasia. in: Foster J.H., Berman M.M. (Eds.) Solid liver tumors. WB Saunders, ; 1977: 138–178 Google Scholar See all References , 2 x [2] Nguyen, B., Flejou, J.F., Terris, B., Belghiti, J., and Degott, C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histological forms. Am J Surg Pathol. 1999; 23: 1441–1458 Crossref | PubMed | Scopus (312) | Google Scholar See all References ]. FNH is more common in premenopausal women, although up to 10% may occur in males [ 3 x [3] Herman, P., Pugliese, V., Machado, M., Montagnini, A.L., Salem, M.Z., and Bacchella, T. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg. 2000; 24: 373–376 Crossref | Scopus (96) | Google Scholar See all References , 4 x [4] Cherqui, D., Rahmouni, A., Charlotte, F., Boulahdour, H., Metreau, J.M., and Meignan, M. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995; 22: 1674–1681 Crossref | PubMed | Google Scholar See all References ]. The lesions are often detected incidentally during imaging for non‐specific symptoms of the abdomen and, once the diagnosis has been established, active treatment is almost never required [ 1 x [1] Foster, J.H. and Berman, M.M. The benign lesions: adenoma and focal nodular hyperplasia. in: Foster J.H., Berman M.M. (Eds.) Solid liver tumors. WB Saunders, ; 1977: 138–178 Google Scholar See all References 1 ]. We present a small series of eight patients with proven FNH who were referred for surgery for relief of symptoms or because of rapid growth. Hepatic resection was undertaken in all patients with excellent outcome.


    • 25 February 2005
      • Vol. 118  (1210) , U1322

    Getting started as a hepatobiliary surgeon: lessons learned from the first 100 hepatectomies as a consultant.

    by Jonathan Koea

    Liver resection has historically been regarded as difficult and dangerous surgery associated with significant perioperative mortality and morbidity rates. Partly as a result of this, adequate training in hepatic surgery has been difficult to obtain with most surgical trainees exposed only to hepatic trauma and damage control scenarios. This report describes the first 100 liver resections undertaken as a surgical consultant. Clinical, diagnostic, pathological, and follow-up data were collected prospectively on 100 patients undergoing liver resection, and was stored in a computerised database. Factors associated with morbidity and trends in operative and perioperative variables over the period of the study were then analysed. Malignant tumours were the most common indication for hepatic resection (88 cases) with 40 resections being undertaken for metastatic colorectal cancer. A further 34 resections were performed for cholangiocarcinoma, gallbladder cancer, or hepatocellular carcinoma. Fifty-six patients underwent a lobectomy (right lobectomy 38, left lobectomy 18)--while a further 13 patients underwent extended resections and 31 patients underwent segmental hepatic resections. The median blood loss for all patients was 375 ml (range 100-5800 ml), and 48 patients required red cell transfusion at any time during their hospital admission. The median hospital stay was 7 days (range 4-38 days), with 52% of the patients developing complications of which 7 patients experienced a major complication, and a 3% mortality rate. The risk of complications was directly related to the magnitude of resection, with 11 of 31 patients undergoing segmental resections developing complications. In comparison, 28 of 56 patients undergoing lobectomy (and all 11 patients undergoing extended resections) developed perioperative complications. Over the study period there was an increase in the use of segmental resections and extended resections with a decrease in blood loss, in-flow occlusion, and mortality. However, hospital stay and morbidity rates remained constant. On multivariate analysis operative blood loss greater than and equal to 1000 ml, resection of greater than and equal to 4 hepatic segments, and the presence of abnormal parenchyma (cirrhosis, steatosis or fibrosis) were independent predictors of perioperative morbidity and mortality. Hepatic resection can be undertaken safely, and increasing experience as a hepatic surgeon is associated with greater utilisation of parenchymal sparing and extended resections (without the routine use of in-flow occlusion).


  • Laparoscopy in the management of colorectal cancer metastatic to the liver

    by Jonathan Koea, Michael Rodgers, Paul Thompson, John Woodfield, Andrew Holden, John McCall

    Background: This investigation was undertaken to define the value of laparoscopy in the staging of patients with colorectal carcinoma metastatic to the liver. Methods: The clinical details of 59 consecutive patients with colorectal liver metastases undergoing laparoscopy prior to planned hepatectomy were entered prospectively on a computerized database. All patients were staged preoperatively with thin slice (5−7 mm) helical computed tomography chest, abdomen and pelvis. Synchronous metastases were defined as those found during, or on imaging carried out within 1 month of, colorectal resection. Criteria for laparoscopic unresectability were: (i) histologically proven extrahepatic disease; (ii) bilateral inflow or outflow involvement; (iii) the presence of cirrhosis in patients requiring an extended resection (lobectomy or greater); or (iv) hepatic metastases involving more than six hepatic segments. Results: In 24 patients with synchronous metastases (median age 65 years, range 32−81 years) all were resectable on laparoscopic criteria, of whom 21 were resected. Extrahepatic disease was found at laparotomy in three patients. In 35 patients with metachronous metastases (median age 64 years, range 32−81 years) laparoscopy could not be performed in five patients because of adhesions, and three patients were deemed unresectable on laparoscopic criteria. Of the remaining 27 patients, 25 underwent resection while two proved unresectable. Overall eight of 54 evaluable patients had unresectable disease and laparoscopy correctly identified three patients. Conclusions: Following computed tomography scan, 15% of patients with metastatic colorectal carcinoma will be found to have unresectable disease. Laparoscopy will identify approximately half. Laparoscopy is of no greater value in staging synchronous versus metachronous metastases.


  • Differential Diagnosis of Stenosing Lesions at the Hepatic Hilus

    by Jonathan Koea, Andrew Holden, Kai Chau, John McCall

    A significant number of stenosing lesions at the hepatic hilus represent benign disease rather than hilar cholangiocarcinoma. It is unclear, however, which perioperative investigations are useful for defining benign lesions in this location. A series of 49 consecutive patients who presented with obstructive jaundice due to a stenosing lesion at the hepatic hilus were investigated by documenting elevated plasma bilirubin levels, the presence of weight loss, and elevated carcinoembryonic antigen (CEA) and Ca 19‐9 concentrations. Radiologic investigations included direct cholangiography, transabdominal ultrasonography, computed tomographic (CT) scans and magnetic resonance imaging (MRI). A tissue diagnosis was obtained in all patients, and the preoperative investigations were reviewed to assess their accuracy for predicting malignancy. The final tissue diagnosis was a benign lesion in 12 patients (benign idiopathic strictures 10, choledocholithiasis 2). Among the 37 patients who presented with a malignant lesion, 2 had metastatic colorectal cancer, 7 had gallbladder cancer, and 28 had hilar cholangiocarcinoma. Of the 12 patients with benign lesions, 4 (33%) had elevated tumor markers (CEA and CA 19‐9), 12 (100%) had cholangiograms suspicious for malignancy, and 9 (75%) had CT and MRI features consistent with a malignant diagnosis. Thus among patients presenting with hilar strictures approximately one‐fifth are due to nonmalignant causes, but the preoperative diagnosis is difficult and resection remains the most reliable way to rule out malignancy in this site.


  • Hepatic adenomas in male patients

    by M. Ronald, J. Woodfield, J. McCall, J. Koea

    Hepatic adenomas are benign tumours of the liver, the growth of which may be positively influenced by oestrogenic hormones [ 1 x 1 Tao, L.‐.C. Oral contraceptive‐associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer. 1991; 68: 341–347 Crossref | PubMed | Scopus (82) | Google Scholar See all References , 2 x 2 Cherqui, D., Rahmouni, A., and Charlotte, F. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995; 22: 1674–1681 Crossref | PubMed | Google Scholar See all References ]; they are most commonly seen in premenopausal women [ 1 x 1 Tao, L.‐.C. Oral contraceptive‐associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer. 1991; 68: 341–347 Crossref | PubMed | Scopus (82) | Google Scholar See all References , 2 x 2 Cherqui, D., Rahmouni, A., and Charlotte, F. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995; 22: 1674–1681 Crossref | PubMed | Google Scholar See all References , 3 x 3 Nagorney, D. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg. 1995; 19: 13–18 Crossref | PubMed | Scopus (129) | Google Scholar See all References ]. A number of reports have documented adenomas in men undergoing steroid therapy [ 4 x 4 Sale, G.E. and Lerner, K.G. Multiple tumors after androgen therapy. Arch Pathol Lab Med. 1977; 101: 600–603 PubMed | Google Scholar See all References 4 ], or in types I and III glycogen storage diseases [ 5 x 5 Howell, R.R., Stevenson, R.E., and Ben‐Menachem, Y. Hepatic adenomata with type I glycogen storage disease. JAMA. 1976; 236: 1481–1484 Crossref | PubMed | Scopus (106) | Google Scholar See all References 5 ]. However, it is now clear that hepatic adenomas may also affect men without these risk factors [ 3 x 3 Nagorney, D. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg. 1995; 19: 13–18 Crossref | PubMed | Scopus (129) | Google Scholar See all References 3 , 6 x 6 Paulson, E., McClellan, J., Washington, K., Spritzer, W., Meyers, W., and Baker, M. Hepatic adenoma: MR characteristics and correlation with pathologic findings. Am J Radiol. 1994; 163: 113–116 Google Scholar See all References , 7 x 7 Weiman, A., Ringe, B., and Klempnauer, J. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg. 1997; 21: 983–991 Crossref | PubMed | Scopus (210) | Google Scholar See all References , 8 x 8 Leese, T., Farges, O., and Bismuth, H. Liver cell adenomas. A 12‐year surgical experience from a specialist hepato‐biliary unit. Ann Surg. 1988; 208: 558–564 Crossref | PubMed | Scopus (204) | Google Scholar See all References , 9 x 9 Mamada, Y., Onda, M., and Tajiri, T. Liver cell adenoma in a 26 year old man. J Nippon Med Sch. 2001; 68: 516–519 Crossref | PubMed | Scopus (6) | Google Scholar See all References ]. While the behaviour of hepatic adenomas in women has been closely evaluated, the specific characteristics of hepatic adenomas in men have not been described.